The purpose of this study was to demonstrate that canakinumab given upon acute gout flares relieves the signs and symptoms and prevents recurrence of gout flares in patients with frequent flares of gout for whom non-steroidal anti-inflammatory drugs (NSAIDs) and/ or colchicine are contraindicated, not tolerated, or ineffective. The efficacy of canakinumab was compared to the corticosteroid triamcinolone acetonide. The purpose of the first 12 week extension study was to collect additional safety, tolerability and efficacy data in patients who have completed the core study CACZ885H2357. The purpose of the second one year open-label extension study was to confirm the long-term safety and tolerability of canakinumab in patients who had completed the first extension study.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Time to First New Flare: Survival Analysis During the 12 Weeks of Study
Timeframe: Baseline to 12 weeks
Self-assessed Pain Intensity in the Joint Most Affected at Baseline Measured on a Visual Analog Scale (VAS) at 72 Hours Post-dose
Timeframe: 72 hours post-dose (randomization)
Number of Participants With Adverse Events, Death and Serious Adverse Events During 24 Weeks
Timeframe: During 24 weeks overall
Number of Participants With Adverse Events, Death and Serious Adverse Events (72 Weeks Overall)
Timeframe: 72 weeks